| Attributes | Values |
|---|
| rdf:type
| |
| http://linked.open...gbank/description
| - Tesamorelin is a stabilized synthetic peptide analogue of the hypothalamic peptide, Growth Hormone Releasing Hormone (GHRH) indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Lipodystrophy is a metabolic condition characterized by insulin resistance, fat redistribution, and hyperlipidemia associated with antiretroviral therapy for HIV infection. (en)
|
| http://linked.open...y/drugbank/dosage
| |
| http://linked.open...generalReferences
| - # Spooner LM, Olin JL: Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother. 2012 Feb;46(2):240-7. doi: 10.1345/aph.1Q629. Epub 2012 Jan 31. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22298602 # McLarnon A: Neuroendocrinology: Tesamorelin can improve cognitive function. Nat Rev Endocrinol. 2012 Oct;8(10):568. doi: 10.1038/nrendo.2012.151. Epub 2012 Aug 28. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22926095 # Bedimo R: Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy. HIV AIDS (Auckl). 2011;3:69-79. doi: 10.2147/HIV.S14561. Epub 2011 Jul 10. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22096409 # Dhillon S: Spotlight on tesamorelin in HIV-associated lipodystrophy. BioDrugs. 2011 Dec 1;25(6):405-8. doi: 10.2165/11208290-000000000-00000. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/22050344 # Garg A: Acquired and inherited lipodystrophies. N Engl J Med. 2004 Mar 18;350(12):1220-34. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15028826 # Patel A, Gandhi H, Upaganlawar A: Tesamorelin: A hope for ART-induced lipodystrophy. J Pharm Bioallied Sci. 2011 Apr;3(2):319-20. doi: 10.4103/0975-7406.80763. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/21687371 # Campbell RM, Lee Y, Rivier J, Heimer EP, Felix AM, Mowles TF: GRF analogs and fragments: correlation between receptor binding, activity and structure. Peptides. 1991 May-Jun;12(3):569-74. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1656403 (en)
|
| http://linked.open...gy/drugbank/group
| - approved (en)
- investigational (en)
|
| http://linked.open...drugbank/halfLife
| - 26 and 38 minutes in healthy subjects and HIV-infected patients, respectively. (en)
|
| http://linked.open...ugbank/indication
| - Tesamorelin acetate is a synthetic analogue of human hypothalamic Growth Hormone Releasing Factor (hGRF) indicated to induce and maintain a reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. (en)
|
| sameAs
| |
| Title
| |
| adms:identifier
| |
| http://linked.open...mechanismOfAction
| - By acting on the pituitary cells in the brain, tesamorelin stimulates production and release of the endogenous hormone (hGRF). Tesamorelin therapy predisposes the patient to glucose intolerance and can also increase the risk of type 2 diabetes, so the drug is contraindicated in pregnancy. (en)
|
| http://linked.open...y/drugbank/patent
| |
| http://linked.open.../drugbank/synonym
| - Egrifta (en)
- Tesamorelin Acetate (en)
- N-(trans-3-Hexenoyl)-Human Growth Hormone Releasing Factor (1-44) Acetate (en)
|
| http://linked.open...drugbank/toxicity
| - Diarrhea, congestive heart failure, peripheral neuropathy, and loss of mobility were the four serious adverse events reported during the clinical studies (en)
|
| http://linked.open...umeOfDistribution
| - 9.4±3.1 L/kg in healthy subjects. 10.5±6.1 L/kg in HIV-infected patients. (en)
|
| foaf:page
| |
| http://linked.open...Molecular-Formula
| |
| http://linked.open.../Molecular-Weight
| |
| http://linked.open...l/drug/hasATCCode
| |
| http://linked.open...ugbank/absorption
| - The absolute bioavailability was determined to be less than 4% in healthy adult subjects following a 2 mg subcutaneous dose. (en)
|
| http://linked.open.../affectedOrganism
| - Humans and other mammals (en)
|
| http://linked.open...casRegistryNumber
| |
| http://linked.open...Isoelectric-Point
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)